SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical Industries informs about company updates

02 Dec 2019 Evaluate

Sun Pharmaceutical Industries has informed that the Company along with its wholly owned subsidiaries (together ‘Sun Pharma’) is a defendant in a multi-district litigation brought by various classes of plaintiffs, in the US District Court (District of Massachusetts), alleging a delay in the market entry for three generic drugs (Valganciclovir, Valsartan and Esomeprazole). The complaints assert claims under the Racketeer Influenced and Corrupt Organizations Act, federal and state antitrust laws, and state consumer protection laws. These litigations have already been disclosed in the Company’s 2018-19 annual report. On November 27, 2019, the US District Court (District of Massachusetts) entered a decision denying in part and granting in part Sun Pharma’s motion to dismiss the claims of certain plaintiffs. Under the ruling the majority of those plaintiff’s claims survive and several state law claims are dismissed. The litigation is proceeding in discovery. Sun Pharma will continue to vigorously defend against all claims and is also considering its appeal options as to the claims that were not dismissed in the above court decision. 

The above information is a part of company’s filings submitted to BSE.

Sun Pharma Inds. Share Price

1825.35 17.15 (0.95%)
04-May-2026 09:12 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1825.35
Dr. Reddys Lab 1315.20
Cipla 1315.60
Zydus Lifesciences 904.55
Lupin 2328.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×